Page last updated: 2024-08-26

melanotan-ii and Hypertension

melanotan-ii has been researched along with Hypertension in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Afghahi, H; Hadimeri, H; Peters, B; Wahlberg, R	1
Carter, CS; Cote, I; Green, SM; Morgan, D; Scarpace, PJ; Toklu, HZ; Tümer, N	1
Bassi, M; da Silva, AA; do Carmo, JM; Hall, JE	1

Reviews

1 review(s) available for melanotan-ii and Hypertension

Article	Year
Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN case reports, 2020, Volume: 9, Issue:2 Topics: Acute Kidney Injury; alpha-MSH; Angiotensin-Converting Enzyme Inhibitors; Diagnostic Errors; Heparin, Low-Molecular-Weight; Humans; Hypertension; Infarction; Kidney; Male; Middle Aged; Penile Erection; Peptides, Cyclic; Receptors, Melanocortin; Rhabdomyolysis; Sexual Arousal; Skin Pigmentation; Tomography, X-Ray Computed; Treatment Outcome	2020

Article

Year

Melanotan II: a possible cause of renal infarction: review of the literature and case report.

CEN case reports, 2020, Volume: 9, Issue:2

Topics: Acute Kidney Injury; alpha-MSH; Angiotensin-Converting Enzyme Inhibitors; Diagnostic Errors; Heparin, Low-Molecular-Weight; Humans; Hypertension; Infarction; Kidney; Male; Middle Aged; Penile Erection; Peptides, Cyclic; Receptors, Melanocortin; Rhabdomyolysis; Sexual Arousal; Skin Pigmentation; Tomography, X-Ray Computed; Treatment Outcome

2020

Other Studies

2 other study(ies) available for melanotan-ii and Hypertension

Article	Year
Limiting feeding to the active phase reduces blood pressure without the necessity of caloric reduction or fat mass loss. American journal of physiology. Regulatory, integrative and comparative physiology, 2018, 10-01, Volume: 315, Issue:4 Topics: Activity Cycles; Adiposity; alpha-MSH; Animals; Arterial Pressure; Diet, High-Fat; Disease Models, Animal; Energy Intake; Energy Metabolism; Fasting; Feeding Behavior; Hypertension; Male; Obesity; Peptides, Cyclic; Photoperiod; Rats, Inbred BN; Rats, Inbred F344; Time Factors	2018
Systemic but not central nervous system nitric oxide synthase inhibition exacerbates the hypertensive effects of chronic melanocortin-3/4 receptor activation. Hypertension (Dallas, Tex. : 1979), 2011, Volume: 57, Issue:3 Topics: alpha-MSH; Analysis of Variance; Animals; Blood Glucose; Body Weight; Catheters, Indwelling; Eating; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Hypertension; Insulin; Leptin; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Peptides, Cyclic; Rats; Rats, Sprague-Dawley; Receptor, Melanocortin, Type 3; Receptor, Melanocortin, Type 4; Telemetry	2011

Article

Year

Limiting feeding to the active phase reduces blood pressure without the necessity of caloric reduction or fat mass loss.

American journal of physiology. Regulatory, integrative and comparative physiology, 2018, 10-01, Volume: 315, Issue:4

Topics: Activity Cycles; Adiposity; alpha-MSH; Animals; Arterial Pressure; Diet, High-Fat; Disease Models, Animal; Energy Intake; Energy Metabolism; Fasting; Feeding Behavior; Hypertension; Male; Obesity; Peptides, Cyclic; Photoperiod; Rats, Inbred BN; Rats, Inbred F344; Time Factors

2018

Systemic but not central nervous system nitric oxide synthase inhibition exacerbates the hypertensive effects of chronic melanocortin-3/4 receptor activation.

Hypertension (Dallas, Tex. : 1979), 2011, Volume: 57, Issue:3

Topics: alpha-MSH; Analysis of Variance; Animals; Blood Glucose; Body Weight; Catheters, Indwelling; Eating; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Hypertension; Insulin; Leptin; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Peptides, Cyclic; Rats; Rats, Sprague-Dawley; Receptor, Melanocortin, Type 3; Receptor, Melanocortin, Type 4; Telemetry

2011